Newron Pharmaceuticals S.p.A.
NP5
Rangering i aksjer
#17660
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Aksjekurs
$10.75
Markedsverdi
$219.74M
Endring (1 dag)
-1.31%
Endring (1 år)
-40.88%
Land
IT
Handel Newron Pharmaceuticals S.p.A. (NP5)
Kategori
Healthcare
Historikk for aksjesplitt for Newron Pharmaceuticals S.p.A. (NP5)
Aksjen Newron Pharmaceuticals S.p.A. (symbol: NP5) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én NP5-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 NP5-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én NP5-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 NP5-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
